Renal Effect Seen In Neupro Lab Values, But Not Robust Enough For Label
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Data supporting an FDA safety reviewer's concerns that laboratory value changes seen in Neupro studies could indicate an effect on renal function were found insufficiently robust for inclusion in labeling by supervisory reviewers, FDA documents show
You may also be interested in...
FDA Review of Schwarz’s Neupro Shaped By Parkinson’s Pharmacovigilance
FDA’s review of the Schwarz Neupro (rotigotine) NDA illustrates the important role pharmacovigilance has come to play in the agency’s consideration of new Parkinson’s disease treatments.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.